4ZG Stock Chart & Stats
€3.22
€0.01(0.25%)
At close: 4:00 PM EST
€3.22
€0.01(0.25%)
Day’s Range― - ―
52-Week Range€1.77 - €6.42
Previous CloseN/A
Volume0.00
Average Volume (3M)81.00
Market Cap
€202.66M
Enterprise Value€180.92
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding49,048,060
10 Day Avg. Volume223
30 Day Avg. Volume81
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio-9.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€25.42M
Bulls Say, Bears Say
Bulls Say
Oncology Imaging & AI FocusA focused business model on oncology imaging and AI targets a durable, growing addressable market tied to cancer diagnostics and drug development. Specialization builds domain expertise, supports defensibility with clinical workflows, and aligns with long-term demand for quantitative imaging in trials.
Diversified Revenue StreamsA mix of clinical-trial services, software licensing/SaaS and potential diagnostic product sales provides multiple, complementary revenue paths. This reduces single-segment dependence, helps stabilize cash flow as software scales, and enables cross-selling into trials and provider markets over time.
Revenue Growth AccelerationAcceleration to ~21.5% revenue growth in 2025 indicates improving market traction for imaging services and software. If sustained, higher top-line growth can better leverage fixed costs, support investment in product development and commercialization, and increase the path toward improved margins.
Bears Say
Negative Shareholders' EquityPersistent negative equity weakens the capital base and reduces financial flexibility. It increases vulnerability to shocks, constrains borrowing capacity, and typically forces reliance on external financing or dilution, making strategic investments and long-term scaling riskier over the medium term.
Consistent Operating Cash BurnChronic negative operating cash flow indicates the business cannot self-fund growth or operations. This ongoing cash burn raises refinancing risk, can delay commercialization efforts or regulatory investments, and may necessitate repeated capital raises that dilute shareholders and distract management.
Deep, Sustained UnprofitabilitySharp negative gross profit and ongoing net losses point to structural margin problems from pricing, cost base or product mix. Absent meaningful improvement in gross margins or a shift to higher-margin software revenue, achieving sustainable profitability will likely require prolonged restructuring or scale-up beyond current horizons.
Median Technologies News
4ZG FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.77 and its highest was €6.42 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €202.66M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 73 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 49,048,060 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.212%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in DE:4ZG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―